Acid Sequence AAGGILHELLV Express Mail Label No.: EL524824544US APPLICATION ELEMENTS INVENTORS: Bernhard Laemmle Helena Elisabeth Gerritsen Miha Furlan Peter Turecek Hans-Peter Schwarz I. X Fee Transmittal Form (Submit an original, and a duplicate for fee processing) 2. X Specification ITotal Pages 3. X Drawing(s) (35 USC §113) [Total Pages (Fig. 1-2) 5] 1 12. X Return Receipt Postcard (MPEP 503) 4. Signed Declaration Total Pages 1 13. Small Entity Statement(s) 5. Copy from a prior application (37 CFR §1.63(d)) 6. (Note Box 5 below) 6. DELETION OF INVENTOR(S) 5. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, see 37 CFR §8.63(d)(2) and 1.33(b) 15. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, see 37 CFR §8.63(d)(2) and 1.33(b) 15. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, see 37 CFR §8.63(d)(2) and 1.33(b) 15. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application is supplied from which a copy of the lates from which a copy of the dath or declaration is supplied		Ţ.	UTILITY PATENT	Docket No.: R-247.00CIP Page 1 of 2			
APPLICATION ELEMENTS ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231 Address Addr		C988	APPLICATION TRANSMITTAL	Title: Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino			
APPLICATION ELEMENTS INVENTORS: Bernhard Learnine Helena Elisabeth Gertisen Man Furlan Elisabeth Gertisen Gerhard Antoline Randoff Kerschbaumer Luigina Tagliavacca Klaus Zimmermann 1.				Acid Sequence AAGGILHLELLV			
INVENTORS: Sembard Learning Friedrich Schefflinger Helena Elisabeth Gerrisen		S	(Under 37 C.F.R. §1.53(b))	Express Mail Label No.: EL524824544US			
Newly executed (original or copy) 1.		PΤ	APPLICATION ELEMENTS	Box Patent Application			
Statement (IDS)/PTO-1449 Citations		O INV	Helena Elisabeth Gerritsen Gerhard Antoine Miha Furlan Randolf Kerschbaumer Peter Turecek Luigina Tagliavacca				
3. X Drawing(s) (35 USC §113) [Total Pages		1.					
Signed Declaration Total Pages 1 13. Small Entity Statement(s) 14. Certified Copy of Priority Documents (s) 14. Certified Copy of Priority Documents (s) 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application original claims before calculating the filing fee 15. Cancel in the application by inserting before the first line the sentence: —This is a Continuation.—This is a		2.	X Specification [Total Pages 32]	2 🚍			
a. Newly executed (original or copy) 14. Certified Copy of Priority Documents (s) b. Copy from a prior application (37 CFR §1.63(d)) (Note Box 5 below) DELETION OF INVENTOR(S) Signed statement attached deleting invento named in the prior application, see 37 CFR §1.63(d)(2) and 1.33(b) Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application and is hereby incorporated by reference therein Nucleotide and/or Amino Acid Sequence Submission Computer Readable Copy Discorporation By Reference Copy (identical to computer copy) Statement Verifying identify of above copies 7. Assignment Papers (cover sheet & document(s)) 14. Certified Copy of Priority Documents (s) 15a. Cancel in the application original claims		3.					
Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b) 5. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein 6. Nucleotide and/or Amino Acid Sequence Submission a. Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifying identify of above copies 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement Papers (cover sheet & document) 9. English Translation Document		4.	Signed Declaration [Total Pages]				
Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b) 15c. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein Nucleotide and/or Amino Acid Sequence Submission a. Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifying identify of above copies 7. Assignment Papers (cover sheet & document(s)) Bigned Statements and the like so made are Punishable by fine or imprisonment, or both, under Section 1001 Of Title 18 of the United States Code and that such willful false Statements may jeopardize the validity of the application or any Patent issuing thereon 15d. Other			a. Newly executed (original or copy)	14. Certified Copy of Priority Documents (s)			
Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b) 15c. Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein Nucleotide and/or Amino Acid Sequence Submission a. Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifying identify of above copies 7. Assignment Papers (cover sheet & document(s)) Biglined statement attached deleting inventor and in the prior application in the prior application in the prior application in the prior application in the state of declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application in the prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the attached papers are a true copy of the lates signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the papers are a true copy of the lates signed prior application number			b. Copy from a prior application (37 CFR §1.63(d))				
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein Nucleotide and/or Amino Acid Sequence Submission a.			i. DELETION OF INVENTOR(S) Signed statement attached deleting invento named in the prior application, see	sentence:This is a Continuation, Divisional, Continuation-in-part, of application/, filed//			
6. Nucleotide and/or Amino Acid Sequence Submission Of Title 18 of the United States Code and that such willful false Statements may jeopardize the validity of the application or any a. Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifiying identify of above copies 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement Power of Attorney 9. English Translation Document Of Title 18 of the United States Code and that such willful false Statements may jeopardize the validity of the application or any Other Other Other Other	h. 11 mil mil 1	5.	entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is	Are true; and further that these statements were made with the Knowledge that willful false statements and the like so made are			
b. Paper Copy (identical to computer copy) Statement Verifiying identify of above copies Patent issuing thereon 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement Power of Attorney 9. English Translation Document		6.	Nucleotide and/or Amino Acid Sequence Submission	Of Title 18 of the United States Code and that such willful false			
7. Assignment Papers (cover sheet & document(s)) 15d. Other		b.	Paper Copy (identical to computer copy)				
8. 37 CFR §3.73(b) Statement Power of Attorney 9. English Translation Document		7	Assignment Papers (cover sheet & document(s))	Patent issuing thereon			
Attorney 15e. Other 9. English Translation Document				15d. Other			
9. English Translation Document		8.		15e. Other			
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:		9.	English Translation Document				
		16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:					
Continuation Divisional Continuation-in-part (CIP) of prior application No.:/							



UTILITY PATENT APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: R-247.00CIP

Page 2 of 2

Title: Composition Exhibiting a von Willebrand Factor (vWF)
Protease Activity Comprising a Polypeptide Chain with the Amino

Acid Sequence AAGGILHLELLV

Express Mail Label No.: EL524824544US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	35-20 =	15	X \$ <u>18</u> =	\$270
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	7-3 =	4	X \$ <u>80</u> =	\$240
	MULTIPLE DEPENDEN (37 CFR §1.16(d))	licable)	+ \$ <u>270 =</u>	\$ 0	
		BASIC FEE (37 CFR §1.16(a))	\$710		
				TOTAL =	\$1220

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket R-247.00CIP). (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. X Fees required under 37 CFR §1.16
- b. X Fees required under 37 CFR §1.17
- c. X Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

SIGNATURE

DATE

Janice Guthrie, Reg. No. 35,170

April 12, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6828 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824544US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on April 12, 2001.

Diane Branham